The price-to-earnings ratio for Biomarin Pharmaceutical Inc (NASDAQ: BMRN) is 21.07x, which is above its average ratio. Moreover, the 36-month beta value for BMRN is 0.18. Analysts have varying opinions on the stock, with 16 analysts rating it as a “buy,” 7 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for BMRN is 189.06M and currently, short sellers hold a 2.35% of that float. On June 04, 2025, BMRN’s average trading volume was 1.89M shares.
BMRN) stock’s latest price update
Biomarin Pharmaceutical Inc (NASDAQ: BMRN)’s stock price has dropped by -0.46 in relation to previous closing price of 57.05. Nevertheless, the company has seen a loss of -2.27% in its stock price over the last five trading days. finbold.com reported 2025-05-30 that The second half of 2025 is fast approaching, and the stock market is promising a crazy ride with some exciting news hitting the headlines.
BMRN’s Market Performance
BMRN’s stock has fallen by -2.27% in the past week, with a monthly drop of -8.45% and a quarterly drop of -19.46%. The volatility ratio for the week is 1.06% while the volatility levels for the last 30 days are 1.78% for Biomarin Pharmaceutical Inc. The simple moving average for the past 20 days is -3.34% for BMRN’s stock, with a -16.55% simple moving average for the past 200 days.
Analysts’ Opinion of BMRN
Many brokerage firms have already submitted their reports for BMRN stocks, with Oppenheimer repeating the rating for BMRN by listing it as a “Outperform.” The predicted price for BMRN in the upcoming period, according to Oppenheimer is $98 based on the research report published on February 24, 2025 of the current year 2025.
Wolfe Research, on the other hand, stated in their research note that they expect to see BMRN reach a price target of $95. The rating they have provided for BMRN stocks is “Outperform” according to the report published on November 15th, 2024.
BMRN Trading at -7.78% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.13% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from Burkhart Erin, who sale 1,786 shares at the price of $59.31 back on May 20 ’25. After this action, Burkhart Erin now owns 14,173 shares of Biomarin Pharmaceutical Inc, valued at $105,928 using the latest closing price.
Burkhart Erin, the Officer of Biomarin Pharmaceutical Inc, proposed sale 1,786 shares at $59.31 during a trade that took place back on May 20 ’25, which means that Burkhart Erin is holding shares at $105,928 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.21 for the present operating margin
- 0.79 for the gross margin
The net margin for Biomarin Pharmaceutical Inc stands at 0.18. The total capital return value is set at 0.09. Equity return is now at value 9.64, with 7.47 for asset returns.
Based on Biomarin Pharmaceutical Inc (BMRN), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at 1.18. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is 96.33.
Currently, EBITDA for the company is 650.86 million with net debt to EBITDA at -0.61. When we switch over and look at the enterprise to sales, we see a ratio of 3.55. The receivables turnover for the company is 3.97for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.52.
Conclusion
To wrap up, the performance of Biomarin Pharmaceutical Inc (BMRN) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
